Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03945721 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients
A Phase 1 study of Triple Negative Breast Cancer and Residual Disease, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 2
- Study locations
NCT03945721 is a Phase 1 study of Triple Negative Breast Cancer and Residual Disease that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 21 participants, below the 246-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT03945721, a Phase 1 study of Triple Negative Breast Cancer and Residual Disease, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 2
- Study locations
Study Summary
This research study involves Niraparib as a possible treatment for triple negative breast cancer.
Conditions Studied
Interventions
- RADIATION Radiation Therapy
- DRUG Niraparib
Study Locations (2)
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Dana Farber Cancer Institute/Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2019-07-11 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03945721
The ClinicalTrials.gov registry entry for NCT03945721 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 246-participant average among 118 other Triple Negative Breast Cancer trials with a reported enrollment target (91% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Triple Negative Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Radiation Therapy is the first listed.
NCT03945721 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03945721 about?
NCT03945721 is a clinical study titled "A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients". This research study involves Niraparib as a possible treatment for triple negative breast cancer.
What is the current status of trial NCT03945721?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2019-07-11. Estimated completion is 2028-12-31.
What conditions does trial NCT03945721 study?
This clinical trial studies the following conditions: Triple Negative Breast Cancer, Residual Disease.
What interventions are being tested in trial NCT03945721?
The interventions under investigation include: Radiation Therapy (RADIATION), Niraparib (DRUG).
Who is sponsoring clinical trial NCT03945721?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03945721 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Triple Negative Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.